Could a common blood thinner replace warfarin for LVAD patients?
NCT ID NCT07471139
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares two blood thinners—apixaban (Eliquis) and warfarin (Coumadin)—in 460 people with advanced heart failure who have a HeartMate 3 heart pump. The goal is to see which drug better prevents strokes, pump clots, and serious bleeding. Participants must have had their pump for at least 3 months and be currently on warfarin.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Apixaban (Eliquis) compared to warfarin (Coumadin)
What this could lead to
If successful, this could offer a simpler, more effective blood thinner for LVAD patients, reducing strokes and bleeding complications.
What could go wrong
This is a phase 3 trial, but it has not yet started recruiting. Apixaban may not prove superior or could have unexpected side effects in this specific device population.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••